Back to search

Article

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines

2021-05-05

Abstract excerpt

The immunological effectiveness of SARS-CoV-2 mRNA vaccines in lung transplant (LT) recipients is largely unknown. Thus, we assessed the effect of Pfizer-BioNTech and Moderna mRNA vaccines’ two-dose (2D) regimen on humoral responses in immunocompromised lung transplant (LT) recipients. About 25% (18/73) of SARS-CoV-2 uninfected-LT patients generated positive spike-IgG response following 2D of vaccines, with 36% (9...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bf15f446-d598-5c18-93fd-871b0d5a53f4
DOI
10.1101/2021.04.26.21255926
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA VaccinesDOI 10.1101/2021.04.26.21255926
Humoral immune responses against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccineSemantic proximity
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysisSemantic proximity
Comparative immunogenicity of heterologous versus homologous 3rd SARS-CoV-2 vaccine doses in kidney transplant recipientsSemantic proximity
A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant RecipientsSemantic proximity
Previous SARS-CoV-2 infection or a third dose of vaccine elicited cross-variant neutralizing antibodies in vaccinated solid organ transplant recipientsSemantic proximity
Safety and Cross-Variant Immunogenicity of a Three-Dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant RecipientsSemantic proximity
B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant RecipientsSemantic proximity
SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA VaccineSemantic proximity
Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipientsSemantic proximity
Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipientsSemantic proximity
BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses Among Transplant Recipients Who Had Received Two Doses of CoronaVacSemantic proximity
HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTSSemantic proximity
Select a neighboring publication to make it the new centre.